Cosmo Pharmaceuticals N.V (C43) — Cash Flow-to-Debt Ratio
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2022, meaning its operating cash flow of €6.28 Million could theoretically repay 0% of its total liabilities (€296.03 Million) in one year. See C43 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cosmo Pharmaceuticals N.V Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Cosmo Pharmaceuticals N.V across 10 annual periods. For the full cash flow conversion analysis, see Cosmo Pharmaceuticals N.V (C43) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Cosmo Pharmaceuticals N.V (2016–2025)
Year-by-year debt coverage analysis for Cosmo Pharmaceuticals N.V. Check C43 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | €-12.48 Million | €123.46 Million | ▼ -108.8% |
| 2024 | 1.15x | €162.41 Million | €141.68 Million | ▲ +317.4% |
| 2023 | 0.27x | €33.62 Million | €122.42 Million | ▲ +144.5% |
| 2022 | 0.11x | €33.23 Million | €295.80 Million | ▲ +160.9% |
| 2021 | 0.04x | €12.61 Million | €292.88 Million | ▼ -35.0% |
| 2020 | 0.07x | €12.98 Million | €196.04 Million | ▲ +167.3% |
| 2019 | -0.10x | €-18.85 Million | €191.43 Million | ▼ -75.2% |
| 2018 | -0.06x | €-10.16 Million | €180.83 Million | ▲ +83.4% |
| 2017 | -0.34x | €-9.43 Million | €27.86 Million | ▼ -143.6% |
| 2016 | 0.78x | €21.69 Million | €27.92 Million | — |